On June 2, 2023 Acorda Therapeutics, Inc. (Nasdaq: ACOR) reported that it has completed the previously announced 1-for-20 reverse stock split of its outstanding and authorized shares of common stock (Press release, Acorda Therapeutics, JUN 2, 2023, View Source [SID1234632383]). The reverse stock split became effective at 4:01 p.m. Eastern Time today, and the Company’s common stock will begin trading on a split-adjusted basis at the market open on June 5, 2023. The reverse stock split was effected to enable the Company to regain compliance with the $1.00 per share minimum closing price required to maintain continued listing on The Nasdaq Global Select Market.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On November 11, 2022, the Company’s stockholders authorized the board of directors to effect a reverse stock split by a ratio of any whole number in the range of 1-for-2 to 1-for-20 and a corresponding reduction in the number of authorized shares of common stock. The board of directors subsequently approved the reverse stock split and authorized the filing of the Company’s amended and restated certificate of incorporation, as previously announced on May 31, 2023.

The Company’s common stock will continue to trade under the symbol "ACOR," and the new CUSIP number for the Company’s common stock following the reverse stock split is 00484M700.

Stockholders owning shares of common stock via a bank, broker, or other nominee will have their positions automatically adjusted to reflect the reverse stock split and will not be required to take further action in connection with the reverse stock split, subject to their brokers’ particular processes.

On June 2, 2023 Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, reported that members of the Aclaris management team will participate in two healthcare investor conferences in June (Press release, Aclaris Therapeutics, JUN 2, 2023, View Source [SID1234632382]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Management will participate in a fireside chat during the 2023 Jefferies Global Healthcare Conference on Thursday, June 8, 2023 at 4:30 PM ET, in New York, NY.

Additionally, management will be participating in a fireside chat during the 44th Annual Goldman Sachs Global Healthcare Conference on Wednesday, June 14, 2023 at 4:40 PM PT/7:40 PM ET, in Dana Point, CA.

Webcasts of the fireside chats may be accessed through the "Events" page of the "Investors" section of Aclaris’ website, www.aclaristx.com. The webcasts will be archived for at least 30 days on the Aclaris website.

On Jume 1, 2023 GI Biome, an affiliate of GI Innovation and a microbiome drug development company, reported that it has started administering GB-X01 to the first patient in the domestic phase 1 clinical trial for colorectal cancer microbiome treatment (Press release, GI Biome, JUN 1, 2023, View Source [SID1234633251]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This clinical trial will be conducted at Samsung Seoul Hospital for patients who have completed standard treatment after radical resection of colorectal cancer. It is planned to evaluate the safety and tolerability of GB-X01 and to confirm changes in the composition of the intestinal microflora before and after administration. It is expected to secure phase 1 results in the second half of this year, including a 4-week dosing period for a total of 9 patients (up to 18) and a 4-week follow-up period thereafter. GB-X01

, obtained through GI Biome’s platform, has a single strain isolated from an adult female as its main component. As an oral drug, the antitumor effect was confirmed in monotherapy and combination therapy. It was said that ‘5-FU’, the most commonly used chemical anticancer drug for the treatment of colorectal cancer, showed a synergistic effect in combination with target anticancer drugs such as bevacizumab and natural killer (NK) cells under development by GI Cell . Based on these preclinical results, we applied for domestic and international patents on materials and uses. The company also confirmed through preclinical studies that it relieves anticancer drug-induced diarrhea ( CID ), which is a typical side effect of anticancer treatment, leading to treatment delay, dose reduction, and treatment discontinuation. A phase 2 plan for mitigating gastrointestinal side effects caused by the toxicity of chemical anticancer drugs is also taking shape.

When phase 1 is completed in the second half of this year, the goal is to apply for phase 2 in Korea early next year. In phase 2, it plans to evaluate the anticancer efficacy through the improvement of side effects caused by chemotherapy and the combination therapy of immune cell therapy.

On June 1, 2023 Triumvira Immunologics presented its corporate presentation (Presentation, Triumvira Immunologics, JUN 1, 2023, View Source [SID1234632480]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On June 2, 2023 Bicara Therapeutics, a clinical-stage biotechnology company developing dual-action biologics designed to modulate the tumor microenvironment to elicit a potent and durable anti-tumor response, reported that Claire Mazumdar, Ph.D., MBA, Chief Executive Officer, will present at the 2023 Jefferies Global Healthcare Conference in New York, NY on Thursday, June 8, 2023 at 11:00 am ET (Press release, Bicara Therapeutics, JUN 1, 2023, View Source;utm_medium=rss&utm_campaign=bicara-therapeutics-to-present-at-the-2023-jefferies-global-healthcare-conference [SID1234632400]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!